Company Description
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications.
The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.
It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments.
In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools.
It serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations.
The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries.
The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015.
Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
| Country | United States |
| Founded | 1990 |
| IPO Date | Jul 23, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 648 |
| CEO | Wenbin Jiang |
Contact Details
Address: 47215 Lakeview Boulevard Fremont, California 94538 United States | |
| Phone | 877 922 9835 |
| Website | cytekbio.com |
Stock Details
| Ticker Symbol | CTKB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001831915 |
| CUSIP Number | 23285D109 |
| ISIN Number | US23285D1090 |
| Employer ID | 47-2547526 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Wenbin Jiang Ph.D. | President, Chief Executive Officer and Chairman of the Board |
| Dr. Ming Yan Ph.D. | Chief Technology Officer and Director |
| Valerie T. Barnett J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Allen B. Poirson Ph.D. | Senior Vice President of Business and Corporate Development |
| Patrik Sebastian Jeanmonod | Head of Corporate Development Analytics |
| William D. McCombe | Chief Financial Officer |
| Dr. Philippe Busque Ph.D. | Senior Vice President of Global Sales and Services |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 28, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 5, 2025 | SCHEDULE 13G/A | Filing |
| Jan 15, 2025 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 5, 2024 | 8-K | Current Report |